Komori
Presentation materials for financial results7681LEOCLAN Co.,Ltd.Trading & Wholesale

Supplementary Explanatory Materials for the Third Quarter of the Fiscal Year Ending September 2026

For the nine months ended June 2026, consolidated revenue was approximately 2.1 times the prior-year period, driven by the consolidation of the ファスキアグループ, while operating profit increased 36%. Net income, however, declined 11.7% due to M&A-related expenses and goodwill amortization, among other factors, and the full-year forecast was left unchanged.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
18975
Millions of yen (year-on-year change in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportQ3 FY20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥36,183 million+110.5%
Operating profit¥644 million+35.7%
Ordinary income¥607 million+23.4%
Net income¥280 million-11.7%
Gross Profit Margin11.7%
Results for the three months of the current quarter
Net Sales
¥11,903 million
EBITDA
¥262 million
Operating profit
¥117 million
Gross Margin
11.7%
Full-year earnings forecast
Net Sales
¥44,500 million
EBITDA
¥1,185 million
Operating profit
¥680 million
Ordinary income
¥610 million
Net income
¥230 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales81.3%
EBITDA89.0%
Operating profit94.7%
Ordinary income99.7%
Net income122.0%
By segment
Medical Total Solution revenue78.1%
Medical Total Solution operating profit116.0%
Teleradiology Services revenue74.1%
Teleradiology Services operating profit80.8%
Minimally Invasive Medical Device Sales revenue85.6%
Minimally Invasive Medical Device Sales operating profit92.2%
Rental revenue74.1%
Rental operating profit70.9%
Other sales75.0%
Other operating profit132.1%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress on revenue from new construction, expansion and renovation projects through Q3 was broadly in line with expectations
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Impact of lower revenue-0.2 Hundreds of millions of yen
  • Change in gross margin-2.1 Hundreds of millions of yen
  • Change in personnel expenses-0.1 Hundreds of millions of yen
  • Change in other SG&A expenses0.1 Hundreds of millions of yen
  • Non-operating income and expenses-0.8 Hundreds of millions of yen
  • Integration of the ファスキアグループ7.8 Hundreds of millions of yen
  • Amortization of goodwill and other items-2 Hundreds of millions of yen
  • Stock acquisition-related expenses-1.5 Hundreds of millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Projected annual revenue from new construction, expansion and renovation projects39 Hundreds of millions of yen
  • Year-on-year change in revenue from new construction, expansion and renovation projectsDown 52%
  • Progress on new construction, expansion and renovation projects through Q364 %
  • Projected ordinary profit for Q4¥2 million
Key KPIsA metric the company considers important as a management benchmark.
  • Net cash39 Hundreds of millions of yen
    Year on year against the same period last yearDown ¥700 million from the end of the previous fiscal year
  • Equity ratio26.1 %
  • Forecast ROE3.5～4.0
  • Hospitals more than 40 years old1,600 buildings
  • Ratio of hospitals more than 40 years old2 Times
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • Number of new construction, expansion and renovation projects under ¥1 billion9 Engagements
    Year on year against the same period last year10 projects in the full fiscal year ended September 2025
  • Average value of new construction, expansion and renovation projects under ¥1 billion¥280 million
    Year on year against the same period last year¥304 million in the full fiscal year ended September 2025
  • Total number of new construction, expansion and renovation projects9 Engagements
    Year on year against the same period last year12 projects in the full fiscal year ended September 2025
  • Average value of all new construction, expansion and renovation projects¥280 million
    Year on year against the same period last year¥676 million in the full fiscal year ended September 2025
Segment results
  • Total Medical Solutions
    Net Sales16,116
    Revenue unit¥ million
    Year-on-year change in revenue-1.1%
    Operating profit177
    Operating profit unit¥ million
    Year-on-year operating profit growth-56.3%
  • Teleradiology Services
    Net Sales616
    Revenue unit¥ million
    Year-on-year change in revenue+0.4%
    Operating profit59
    Operating profit unit¥ million
    Year-on-year operating profit growth+0.6%
  • Minimally Invasive Medical Device Sales
    Net Sales17,626
    Revenue unit¥ million
    Operating profit350
    Operating profit unit¥ million
  • Rental
    Net Sales467
    Revenue unit¥ million
    Operating profit62
    Operating profit unit¥ million
  • Other
    Net Sales1,358
    Revenue unit¥ million
    Year-on-year change in revenue4.5 times prior-year period
    Operating profit55
    Operating profit unit¥ million
    Year-on-year operating profit growth6.6 times prior-year period
  • Adjustments
    Operating profit-60
    Operating profit unit¥ million
Market Size / Share
Approximately 1,600 hospitals more than 40 years old, representing approximately 20% of the 8,728 hospitals surveyed
Number of employees
Number of Employees353 people
Change during the periodIncreased from 155 people in the fiscal year ended September 2025
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredQ3 FY2026
Net Sales¥36,183 million (YoY +110.5%)
Operating profit¥644 million (YoY +35.7%)
Ordinary income¥607 million (YoY +23.4%)
Net income¥280 million (YoY -11.7%)
Gross Profit Margin11.7%
Results for the three months of the current quarterNet Sales ¥11,903 million / EBITDA ¥262 million / Operating profit ¥117 million / Gross Margin 11.7%
Full-year earnings forecastNet Sales ¥44,500 million / EBITDA ¥1,185 million / Operating profit ¥680 million / Ordinary income ¥610 million / Net income ¥230 million
Progress against full-year forecastNet Sales 81.3% / EBITDA 89.0% / Operating profit 94.7% / Ordinary income 99.7% / Net income 122.0% / By segment Medical Total Solution revenue 78.1% / Medical Total Solution operating profit 116.0% / Teleradiology Services revenue 74.1% / Teleradiology Services operating profit 80.8% / Minimally Invasive Medical Device Sales revenue 85.6% / Minimally Invasive Medical Device Sales operating profit 92.2% / Rental revenue 74.1% / Rental operating profit 70.9% / Other sales 75.0% / Other operating profit 132.1%
Self-assessment against the planProgress on revenue from new construction, expansion and renovation projects through Q3 was broadly in line with expectations
Segment resultsSegment Total Medical Solutions / Net Sales 16,116 / Revenue unit ¥ million / Year-on-year change in revenue -1.1% / Operating profit 177 / Operating profit unit ¥ million / Year-on-year operating profit growth -56.3%, Segment Teleradiology Services / Net Sales 616 / Revenue unit ¥ million / Year-on-year change in revenue +0.4% / Operating profit 59 / Operating profit unit ¥ million / Year-on-year operating profit growth +0.6%, Segment Minimally Invasive Medical Device Sales / Net Sales 17,626 / Revenue unit ¥ million / Year-on-year change in revenue Not disclosed / Operating profit 350 / Operating profit unit ¥ million / Year-on-year operating profit growth Not disclosed, Segment Rental / Net Sales 467 / Revenue unit ¥ million / Year-on-year change in revenue Not disclosed / Operating profit 62 / Operating profit unit ¥ million / Year-on-year operating profit growth Not disclosed, Segment Other / Net Sales 1,358 / Revenue unit ¥ million / Year-on-year change in revenue 4.5 times prior-year period / Operating profit 55 / Operating profit unit ¥ million / Year-on-year operating profit growth 6.6 times prior-year period, Segment Adjustments / Net Sales Not disclosed / Operating profit -60 / Operating profit unit ¥ million / Year-on-year operating profit growth Not disclosed
Breakdown of Factors Affecting the ChangeFactors Impact of lower revenue / Amount -0.2 Hundreds of millions of yen, Factors Change in gross margin / Amount -2.1 Hundreds of millions of yen, Factors Change in personnel expenses / Amount -0.1 Hundreds of millions of yen, Factors Change in other SG&A expenses / Amount 0.1 Hundreds of millions of yen, Factors Non-operating income and expenses / Amount -0.8 Hundreds of millions of yen, Factors Integration of the ファスキアグループ / Amount 7.8 Hundreds of millions of yen, Factors Amortization of goodwill and other items / Amount -2 Hundreds of millions of yen, Factors Stock acquisition-related expenses / Amount -1.5 Hundreds of millions of yen
Key KPIsIndicator name Net cash / Value 39 Hundreds of millions of yen / Year on year against the same period last year Down ¥700 million from the end of the previous fiscal year, Indicator name Equity ratio / Value 26.1 % / Year on year against the same period last year Not disclosed, Indicator name Forecast ROE / Value 3.5～4.0 / Year on year against the same period last year Not disclosed, Indicator name Hospitals more than 40 years old / Value 1,600 buildings / Year on year against the same period last year Not disclosed, Indicator name Ratio of hospitals more than 40 years old / Value 2 Times / Year on year against the same period last year Not disclosed
Unit price and quantity metricsIndicator name Number of new construction, expansion and renovation projects under ¥1 billion / Value 9 Engagements / Year on year against the same period last year 10 projects in the full fiscal year ended September 2025, Indicator name Average value of new construction, expansion and renovation projects under ¥1 billion / Value ¥280 million / Year on year against the same period last year ¥304 million in the full fiscal year ended September 2025, Indicator name Total number of new construction, expansion and renovation projects / Value 9 Engagements / Year on year against the same period last year 12 projects in the full fiscal year ended September 2025, Indicator name Average value of all new construction, expansion and renovation projects / Value ¥280 million / Year on year against the same period last year ¥676 million in the full fiscal year ended September 2025
Number of employeesNumber of Employees 353 people / Change during the period Increased from 155 people in the fiscal year ended September 2025
Assumptions Underlying the Business OutlookItem Projected annual revenue from new construction, expansion and renovation projects / Value 39 Hundreds of millions of yen, Item Year-on-year change in revenue from new construction, expansion and renovation projects / Value Down 52%, Item Progress on new construction, expansion and renovation projects through Q3 / Value 64 %, Item Projected ordinary profit for Q4 / Value ¥2 million
Market Size / ShareMarket Size Approximately 1,600 hospitals more than 40 years old, representing approximately 20% of the 8,728 hospitals surveyed / Share Not disclosed
Items this document does not state (13)
Operating profit marginSelling, general and administrative expensesNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The consolidation of the ファスキアグループ, which joined the group at the beginning of the fiscal year, boosted revenue and profit. In the former レオクラングループ, gross margin in the Medical Total Solution business declined as highly profitable projects from the prior year ran their course. Profit was also weighed down by interest expenses associated with increased borrowings, goodwill amortization, and stock acquisition-related expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Explanatory Materials for the Third Quarter of the Fiscal Year Ending September 2026 | LEOCLAN Co.,Ltd. (7681) timely disclosure | Komori